BMS leases biologic development space in New Jersey to PTC

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: Bms, Biologics, development, New jersey

Bristol-Myers Squibb and PTC Therapeutics enter a long-term lease agreement giving the latter greater access to biologic production facility as it advances its treatments for rare genetic disorders.

PTC Therapeutics signed a long-term lease agreement with Bristol-Myers Squibb (BMS) to gain access to a 185,000 square foot space in Hopewell, NJ. The site, located on BMS’ property, includes a biologics production facility, and research and operations buildings.

With this 15-year lease agreement, PTC plans to further develop the biologics facility in an aim to support its gene therapy production capabilities. The site’s current good manufacturing practice (cGMP) suites will be used to produce material to serve PTC’s pre-clinical and clinical programs.

The company focuses on developing treatments for rare genetic disorders, specifically, therapies for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA).

Additionally, PTC intends to move its research operations to the site complementing existing operations at the company’s existing New Jersey productions. A spokesperson for the company told us that PTC has been in New Jersey for over 21 years.

PTC also stated that it has plans to relocate and expand its discovery and research operations to the site in 2020.

Related topics: Downstream Processing, Cell lines

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars